drugset / Trial / NCT01122368

A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects

NCT01122368

Phase 2 Completed 252 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Subjects with intra-abdominal infection requiring surgery and Intensive Care Unit stay will be treated early with micafungin or placebo to determine the incidence and time to confirmation of fungal infection.

Timeline

Start
2010-07-13
Primary completion
2011-12-15
Completion
2011-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide 100 mg